Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
Stephany H DonzeRenske J KuppensNienke E BakkerJaniëlle A E M van Alfen-van der VeldenAnita C S Hokken-KoelegaPublished in: Clinical endocrinology (2018)
Compared to GH treatment, 1 year of placebo after attainment of AH does not deteriorate BMD SDS in young adults with PWS. In addition, our data suggest that GH is not able to prevent the decline in BMD SDS in hypogonadal young adults with PWS, unless it is combined with SSRT.
Keyphrases
- growth hormone
- bone mineral density
- placebo controlled
- phase iii
- double blind
- young adults
- postmenopausal women
- phase ii
- study protocol
- body composition
- open label
- clinical trial
- middle aged
- replacement therapy
- phase ii study
- randomized controlled trial
- electronic health record
- case report
- big data
- squamous cell carcinoma
- combination therapy
- radiation therapy
- childhood cancer
- artificial intelligence
- deep learning